Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.225 USD | +1.54% | -11.10% | +1.48% |
Jun. 01 | Transcript : Iovance Biotherapeutics, Inc. - Special Call | |
May. 13 | Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.48% | 2.27B | |
+16.86% | 3.43B | |
-19.52% | 2.03B | |
-20.54% | 1.63B | |
+31.45% | 1.16B | |
+17.67% | 714M | |
-9.39% | 703M | |
-21.12% | 500M | |
-1.29% | 279M | |
-15.53% | 161M |
- Stock Market
- Equities
- IOVA Stock
- News Iovance Biotherapeutics, Inc.
- Goldman Sachs Downgrades Iovance Biotherapeutics to Neutral From Buy, Adjusts Price Target to $6 From $20